Projects per year
Abstract
Targeting PPIs with small molecules can be challenging owing to large, hydrophobic binding surfaces. Herein, we describe a strategy that exploits selective α-helical PPIs, transferring these characteristics to small molecules. The proof of concept is demonstrated with the apoptosis regulator Mcl-1, commonly exploited by cancers to avoid cell death. Peptide-directed binding uses few synthetic transformations, requires the production of a small number of compounds, and generates a high percentage of hits. In this example, about 50 % of the small molecules prepared showed an IC50 value of less than 100 μm, and approximately 25 % had IC50 values below 1 μm to Mcl-1. Compounds show selectivity for Mcl-1 over other anti-apoptotic proteins, possess cytotoxicity to cancer cell lines, and induce hallmarks of apoptosis. This approach represents a novel and economic process for the rapid discovery of new α-helical PPI modulators.
Original language | English |
---|---|
Pages (from-to) | 10446–10450 |
Number of pages | 5 |
Journal | Angewandte Chemie-International Edition |
Volume | 56 |
Issue number | 35 |
Early online date | 25 Jul 2017 |
DOIs | |
Publication status | Published - 21 Aug 2017 |
Keywords
- apoptosis
- drug discovery
- medicinal chemistry
- protein–protein interactions
- solid-phase synthesis
Profiles
-
Andrew Beekman
- School of Chemistry, Pharmacy and Pharmacology - Associate Professor in Medicinal Chemistry
Person: Academic, Teaching & Research
-
Maria O'Connell
- Faculty of Science - Associate Dean for Research
- School of Chemistry, Pharmacy and Pharmacology - Professor of Cell Biology
- Molecular and Tissue Pharmacology - Group Lead
- HealthUEA - Steering Committee Member
Person: Research Group Member, Academic, Teaching & Research
Projects
- 1 Finished